Decitabine improves patient outcomes in myelodysplastic syndromes

20061,507 citationsJournal Article

Authors

Hagop M. Kantarjian · The University of Texas MD Anderson Cancer Center

Jean‐Pierre J. Issa · The University of Texas MD Anderson Cancer Center

C Rosenfeld

John M. Bennett · University of Rochester Medical Center

Maher Albitar · Quest Diagnostics (United States)

John F. DiPersio · Washington University in St. Louis

Virginia M. Klimek · Memorial Sloan Kettering Cancer Center

Abstract

Decitabine was found to be clinically effective in the treatment of patients with MDS, provided durable responses, and improved time to AML transformation or death. The duration of decitabine therapy may improve these results further.

Topics & Keywords

Acute Myeloid Leukemia Research Epigenetics and DNA Methylation Acute Lymphoblastic Leukemia research

UN Sustainable Development Goals

Partnerships for the goals

Publication Details

Published in: Cancer

Volume 106, Issue 8, pp. 1794-1803

DOI: 10.1002/cncr.21792

Field-Weighted Citation Impact: 39.55